The Impact of Systemic Lupus Erythematosus Flares on Clinical and Economic Outcomes: The CHAMOMILE Claims Database Study in Germany
Abstract Introduction CHAMOMILE (CHaracteristics and impact of flares on clinicAl and econoMic OutcoMes In patients with systemic Lupus Erythematosus [SLE]) examined how flares in the year of SLE diagnosis impact future disease activity and damage, productivity, healthcare resource utilization (HCRU...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2024-01-01
|
| Series: | Rheumatology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40744-023-00635-0 |
| _version_ | 1797266634480549888 |
|---|---|
| author | Bo Ding Marc Pignot Elena Garal-Pantaler Beate Villinger Sebastian Schefzyk Barnabas Desta Heide A. Stirnadel-Farrant Andreas Schwarting |
| author_facet | Bo Ding Marc Pignot Elena Garal-Pantaler Beate Villinger Sebastian Schefzyk Barnabas Desta Heide A. Stirnadel-Farrant Andreas Schwarting |
| author_sort | Bo Ding |
| collection | DOAJ |
| description | Abstract Introduction CHAMOMILE (CHaracteristics and impact of flares on clinicAl and econoMic OutcoMes In patients with systemic Lupus Erythematosus [SLE]) examined how flares in the year of SLE diagnosis impact future disease activity and damage, productivity, healthcare resource utilization (HCRU), and costs in patients with SLE in Germany. Methods CHAMOMILE was a retrospective cohort study of adults with an SLE diagnosis in the German Sickness Fund Database from 1 July 2010 to 31 December 2013. Patients were classified according to their greatest flare severity during the baseline year (none, mild, or moderate/severe). The number and severity of flares were assessed annually over 5–8.5 follow-up years, along with SLE organ/system damage, treatments, work disability, and HCRU metrics. Results Of 2088 patients (84.6% female; mean age [standard deviation] 51.4 [16.1] years; mean follow-up 6.8 [2.1] years), 34.3% (n = 716) were flare-free, 29.8% (n = 622) had mild flares, and 35.9% (n = 750) had moderate/severe flares at baseline. Baseline flare severity was related to future flares: rates during follow-up were higher in patients with moderate/severe baseline flares compared with those with mild or no baseline flares (89.6 vs 78.5 and 44.2 flares/100 patient years, respectively). Overall, 80.2% (n = 1675) of patients received glucocorticoids at least once during baseline and follow-up. Patients’ HCRU was generally greatest in their baseline year. Costs were highest in patients with moderate/severe baseline flares. Conclusion Baseline flare severity provided insight into a patient’s disease course and the clinical and economic burden of SLE over time, highlighting the ramifications of uncontrolled disease for patients with SLE. |
| first_indexed | 2024-04-25T01:03:49Z |
| format | Article |
| id | doaj.art-64dca17cc34e46928ce38d485baf8fc9 |
| institution | Directory Open Access Journal |
| issn | 2198-6576 2198-6584 |
| language | English |
| last_indexed | 2024-04-25T01:03:49Z |
| publishDate | 2024-01-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Rheumatology and Therapy |
| spelling | doaj.art-64dca17cc34e46928ce38d485baf8fc92024-03-10T12:21:49ZengAdis, Springer HealthcareRheumatology and Therapy2198-65762198-65842024-01-0111228529910.1007/s40744-023-00635-0The Impact of Systemic Lupus Erythematosus Flares on Clinical and Economic Outcomes: The CHAMOMILE Claims Database Study in GermanyBo Ding0Marc Pignot1Elena Garal-Pantaler2Beate Villinger3Sebastian Schefzyk4Barnabas Desta5Heide A. Stirnadel-Farrant6Andreas Schwarting7BioPharmaceuticals Medical, AstraZenecaCenter of Epidemiology and Health Research Berlin, ZEG Berlin GmbHHealth Economics Department, Team Gesundheit GmbHBioPharmaceuticals Medical, AstraZenecaBioPharmaceuticals Medical, AstraZenecaBioPharmaceuticals Business Unit, AstraZenecaOncology Business Unit Medical, AstraZenecaCenter for Rheumatic Disease Rhineland-PalatinateAbstract Introduction CHAMOMILE (CHaracteristics and impact of flares on clinicAl and econoMic OutcoMes In patients with systemic Lupus Erythematosus [SLE]) examined how flares in the year of SLE diagnosis impact future disease activity and damage, productivity, healthcare resource utilization (HCRU), and costs in patients with SLE in Germany. Methods CHAMOMILE was a retrospective cohort study of adults with an SLE diagnosis in the German Sickness Fund Database from 1 July 2010 to 31 December 2013. Patients were classified according to their greatest flare severity during the baseline year (none, mild, or moderate/severe). The number and severity of flares were assessed annually over 5–8.5 follow-up years, along with SLE organ/system damage, treatments, work disability, and HCRU metrics. Results Of 2088 patients (84.6% female; mean age [standard deviation] 51.4 [16.1] years; mean follow-up 6.8 [2.1] years), 34.3% (n = 716) were flare-free, 29.8% (n = 622) had mild flares, and 35.9% (n = 750) had moderate/severe flares at baseline. Baseline flare severity was related to future flares: rates during follow-up were higher in patients with moderate/severe baseline flares compared with those with mild or no baseline flares (89.6 vs 78.5 and 44.2 flares/100 patient years, respectively). Overall, 80.2% (n = 1675) of patients received glucocorticoids at least once during baseline and follow-up. Patients’ HCRU was generally greatest in their baseline year. Costs were highest in patients with moderate/severe baseline flares. Conclusion Baseline flare severity provided insight into a patient’s disease course and the clinical and economic burden of SLE over time, highlighting the ramifications of uncontrolled disease for patients with SLE.https://doi.org/10.1007/s40744-023-00635-0FlareGlucocorticoidsHealthcare resource utilizationSystemic lupus erythematosus |
| spellingShingle | Bo Ding Marc Pignot Elena Garal-Pantaler Beate Villinger Sebastian Schefzyk Barnabas Desta Heide A. Stirnadel-Farrant Andreas Schwarting The Impact of Systemic Lupus Erythematosus Flares on Clinical and Economic Outcomes: The CHAMOMILE Claims Database Study in Germany Rheumatology and Therapy Flare Glucocorticoids Healthcare resource utilization Systemic lupus erythematosus |
| title | The Impact of Systemic Lupus Erythematosus Flares on Clinical and Economic Outcomes: The CHAMOMILE Claims Database Study in Germany |
| title_full | The Impact of Systemic Lupus Erythematosus Flares on Clinical and Economic Outcomes: The CHAMOMILE Claims Database Study in Germany |
| title_fullStr | The Impact of Systemic Lupus Erythematosus Flares on Clinical and Economic Outcomes: The CHAMOMILE Claims Database Study in Germany |
| title_full_unstemmed | The Impact of Systemic Lupus Erythematosus Flares on Clinical and Economic Outcomes: The CHAMOMILE Claims Database Study in Germany |
| title_short | The Impact of Systemic Lupus Erythematosus Flares on Clinical and Economic Outcomes: The CHAMOMILE Claims Database Study in Germany |
| title_sort | impact of systemic lupus erythematosus flares on clinical and economic outcomes the chamomile claims database study in germany |
| topic | Flare Glucocorticoids Healthcare resource utilization Systemic lupus erythematosus |
| url | https://doi.org/10.1007/s40744-023-00635-0 |
| work_keys_str_mv | AT boding theimpactofsystemiclupuserythematosusflaresonclinicalandeconomicoutcomesthechamomileclaimsdatabasestudyingermany AT marcpignot theimpactofsystemiclupuserythematosusflaresonclinicalandeconomicoutcomesthechamomileclaimsdatabasestudyingermany AT elenagaralpantaler theimpactofsystemiclupuserythematosusflaresonclinicalandeconomicoutcomesthechamomileclaimsdatabasestudyingermany AT beatevillinger theimpactofsystemiclupuserythematosusflaresonclinicalandeconomicoutcomesthechamomileclaimsdatabasestudyingermany AT sebastianschefzyk theimpactofsystemiclupuserythematosusflaresonclinicalandeconomicoutcomesthechamomileclaimsdatabasestudyingermany AT barnabasdesta theimpactofsystemiclupuserythematosusflaresonclinicalandeconomicoutcomesthechamomileclaimsdatabasestudyingermany AT heideastirnadelfarrant theimpactofsystemiclupuserythematosusflaresonclinicalandeconomicoutcomesthechamomileclaimsdatabasestudyingermany AT andreasschwarting theimpactofsystemiclupuserythematosusflaresonclinicalandeconomicoutcomesthechamomileclaimsdatabasestudyingermany AT boding impactofsystemiclupuserythematosusflaresonclinicalandeconomicoutcomesthechamomileclaimsdatabasestudyingermany AT marcpignot impactofsystemiclupuserythematosusflaresonclinicalandeconomicoutcomesthechamomileclaimsdatabasestudyingermany AT elenagaralpantaler impactofsystemiclupuserythematosusflaresonclinicalandeconomicoutcomesthechamomileclaimsdatabasestudyingermany AT beatevillinger impactofsystemiclupuserythematosusflaresonclinicalandeconomicoutcomesthechamomileclaimsdatabasestudyingermany AT sebastianschefzyk impactofsystemiclupuserythematosusflaresonclinicalandeconomicoutcomesthechamomileclaimsdatabasestudyingermany AT barnabasdesta impactofsystemiclupuserythematosusflaresonclinicalandeconomicoutcomesthechamomileclaimsdatabasestudyingermany AT heideastirnadelfarrant impactofsystemiclupuserythematosusflaresonclinicalandeconomicoutcomesthechamomileclaimsdatabasestudyingermany AT andreasschwarting impactofsystemiclupuserythematosusflaresonclinicalandeconomicoutcomesthechamomileclaimsdatabasestudyingermany |